GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (OTCPK:SNBIF) » Definitions » Profitability Rank

SanBio Co (SanBio Co) Profitability Rank : 1 (As of Jan. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Profitability Rank?

SanBio Co has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

SanBio Co's Operating Margin % for the quarter that ended in Jan. 2024 was %. As of today, SanBio Co's Piotroski F-Score is 2.


Competitive Comparison of SanBio Co's Profitability Rank

For the Biotechnology subindustry, SanBio Co's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Profitability Rank distribution charts can be found below:

* The bar in red indicates where SanBio Co's Profitability Rank falls into.



SanBio Co Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

SanBio Co has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

SanBio Co's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=-5.567 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

SanBio Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


SanBio Co Profitability Rank Related Terms

Thank you for viewing the detailed overview of SanBio Co's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (SanBio Co) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (SanBio Co) Headlines

From GuruFocus

Q2 2021 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2021 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2019 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2023 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2024 SanBio Co Ltd Earnings Presentation Transcript

By GuruFocus Research 02-15-2024

Q2 2022 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024